Bert I. Rowland

Bert I. Rowland

Keine laufenden Positionen mehr
Energy Minerals
Health Services
Commercial Services

Profil

Dr. Rowland is currently with Shalon Ventures.
He has practiced patent law and has written seminal patents in diagnostics, molecular biology (including the Cohen Boyer cloning patent for Stanford and UC, the first patent in biotechnology), cell biology, agricultural biology, combinatorial chemistry, contrast media, calcium phosphates for the treatment of bone, and chemical reactions (particularly epoxidation), for a total of over 500 patents.
He first worked for Chevron as patent counsel.
He has been a partner of Townsend & Townsend and Leydig, Voit & Mayer and Of Counsel to other law firms.
He was president of Drug Abuse Sciences and General Counsel of SyStemix.
He was instrumental or played a major role in the founding of many start-up companies, including SyStemix, Pharmacopoeia, Calgene, Immulogic Pharmaceuticals, Molecular Devices, Receptron, and Matrix Pharmaceutical, and played a prominent role with numerous other start-up companies.
Dr. Rowland holds both a PhD in Organic Chemistry and a JD, Order of the Coif.

Ehemalige bekannte Positionen von Bert I. Rowland

UnternehmenPositionEnde
General Counsel -
CHEVRON CORPORATION Corporate Officer/Principal -
Corporate Officer/Principal -
General Counsel 12.01.2011
Sehen Sie sich die Erfahrung von Bert I. Rowland im Detail an

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Unternehmensverbindungen

Private Unternehmen4

Energy Minerals

Health Services

Commercial Services

Finance

  1. Börse
  2. Insiders
  3. Bert I. Rowland